Skip Navigation
Skip to contents
Results by Year

View Wide

Filter

ARTICLE TYPE

more+
SELECT FILTER
 
Close

PUBLICATION DATE

7 results
Display

Mechanisms of Platelet Activation and Integrin alphaIIbeta3

Joo SJ

Platelet aggregation is not only an essential part of hemostasis, but also initiates acute coronary syndrome or ischemic stroke. The precise understanding of the activation mechanism of platelet aggregation is...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Effects of Cilostazol on Platelet Activation in Coronary Stenting Patients Who Already Treated with Aspirin and Clopidogrel

Ahn JC, Song WH, Kwon JA, Park CG, Seo HS, Oh DJ, Rho YM

  • KMID: 1109521
  • Korean J Intern Med.
  • 2004 Dec;19(4):230-236.
BACKGROUND: A recent study has shown that triple anti-platelet therapy (cilostazol+clopidogrel+aspirin) resulted in a significantly lower restenosis rate after coronary stenting than did conventional therapy (clopidogrel+aspirin). However, the anti-platelet effects...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Anti-thrombotic activity of fermented rice bran extract with several oriental plants in vitro and in vivo

Jeon BR, Ji HD, Kim SJ, Lee CH, Kim TW, Rhee MH

Although the effects of the rice bran have recently been investigated, there is no information regarding platelet physiology available. However, it is well known that fermented natural plants have a...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
A Multicenter, Randomized, Open-Label, Therapeutic, and Exploratory Trial to Evaluate the Tolerability and Efficacy of Platelet Glycoprotein IIb/IIIa Receptor Blocker (Clotinab(TM)) in High-Risk Patients with Percutaneous Coronary Intervention

Moon JY, Kim W, Kim JH, Ahn Y, Jeong MH, Kim YH, Hong MK, Park SW, Park SJ, Park S, Ko YG, Choi D, Jang Y

PURPOSE: This study was designed as a multicenter, randomized, open-label study to evaluate the efficacy and tolerability of Clotinab(TM). We expected to obtain same results as with ReoPro(R) in improving...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
The Long-term Clinical Results of a Platelet Glycoprotein IIb/IIIa Receptor Blocker (Abciximab: ReoPro (R) ) Coated Stent in Patients with Coronary Artery Disease

Kim W, Jeong MH, Hong YJ, Lee SH, Park WS, Kim JH, Kim IS, Choi MJ, Ahn YK, Cho JG, Park JC, Cho DL, Kim H, Kang JC

  • KMID: 1109520
  • Korean J Intern Med.
  • 2004 Dec;19(4):220-229.
BACKGROUND: Previously, the inhibition of coronary restenosis with Abciximab (ReoPro (R) ) -coated stent in a porcine model was reported. ReoPro (R) inhibits platelet aggregation, the proliferation of vascular smooth...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Clinical Benefit of Low Molecular Weight Heparin for ST-segment Elevation Myocardial Infarction Patients Undergoing Primary Percutaneous Coronary Intervention with Glycoprotein IIb/IIIa Inhibitor

Cho JS, Her SH, Baek JY, Park MW, Kim HD, Jeong MH, Ahn YK, Chae SC, Hur SH, Hong TJ, Kim YJ, Seong IW, Chae JK, Rhew JY, Chae IH, Cho MC, Bae JH, Rha SW, Kim CJ, Choi D, Jang YS, Yoon J, Chung WS, Cho JG, Seung KB, Park SJ

The efficacy of low molecular weight heparin (LMWH) with low dose unfractionated heparin (UFH) during percutaneous coronary intervention (PCI) with or without glycoprotein (Gp) IIb/IIIa inhibitor compared to UFH with...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Long-Term Clinical Benefits of a Platelet Glycoprotein IIb/IIIa Receptor Blocker, Abciximab (ReoPro (R) ), in High-Risk Diabetic Patients undergoing Percutaneous Coronary Intervention

Sim DS, Jeong MH, Kim W, Rhew JY, Yum JH, Kim JH, Cho JG, Ahn YK, Park JC, Ahn BH, Kim SH, Kang JC

  • KMID: 759651
  • Korean J Intern Med.
  • 2003 Sep;18(3):129-137.
BACKGROUND: High-risk percutaneous coronary interventions (PCIs) are associated with a high complication rate, a low procedural success rate and a high restenosis rate, especially in diabetics. We sought to determine...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close

Go to Top

Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr